Linking SLAMF1 to autophagy and sensitivity to therapy in chronic lymphocytic leukemia

4Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We recently reported that expression of the costimulatory molecule and microbial sensor SLAMF1 (signaling lymphocytic activation molecule family 1, also known as CD150) is lost in chronic lymphocytic leukemia (CLL) patients characterized by a shorter overall survival. SLAMF1 modulates CLL responses to chemokines and regulates autophagy. Loss of SLAMF1 renders CLL cells relatively unresponsive to autophagy-inducing drugs, including B-cell CLL/lymphoma 2 (BCL2) inhibitors.

Author supplied keywords

Cite

CITATION STYLE

APA

Bologna, C., & Deaglio, S. (2018). Linking SLAMF1 to autophagy and sensitivity to therapy in chronic lymphocytic leukemia. Molecular and Cellular Oncology, 5(3). https://doi.org/10.1080/23723556.2016.1143077

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free